147 related articles for article (PubMed ID: 37423585)
1. ERBB2 Amplification and HER2 Expression in Salivary Duct Carcinoma: Evaluation of Scoring Guidelines and Potential for Expanded Anti-HER2 Therapy.
McAfee JL; Hoda RS; Hoyle C; McCoy L; Sprague C; Reddy CA; Koyfman SA; Geiger JL; Komforti MK; Griffith CC
Mod Pathol; 2023 Oct; 36(10):100273. PubMed ID: 37423585
[TBL] [Abstract][Full Text] [Related]
2. ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing.
Ferguson DC; Momeni Boroujeni A; Zheng T; Mohanty AS; Ho AL; Arcila ME; Ross DS; Dogan S
Mod Pathol; 2022 Jul; 35(7):895-902. PubMed ID: 34963694
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral heterogeneity of HER2 protein and amplification of HER2 gene in salivary duct carcinoma.
Kondo Y; Kikuchi T; Esteban JC; Kumaki N; Ogura G; Inomoto C; Hirabayashi K; Kajiwara H; Sakai A; Sugimoto R; Otsuru M; Okami K; Tsukinoki K; Nakamura N
Pathol Int; 2014 Sep; 64(9):453-9. PubMed ID: 25209856
[TBL] [Abstract][Full Text] [Related]
4. The implications of TrkA and MET aberrations in de novo salivary duct carcinoma.
Ryu HJ; Koh YW; Yoon SO
Hum Pathol; 2018 Nov; 81():18-25. PubMed ID: 29753009
[TBL] [Abstract][Full Text] [Related]
5. Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays.
Robinson CL; Harrison BT; Ligon AH; Dong F; Maffeis V; Matulonis U; Nucci MR; Kolin DL
Mod Pathol; 2021 Mar; 34(3):603-612. PubMed ID: 33077919
[TBL] [Abstract][Full Text] [Related]
6. Role of HER2 in Prognosis of Salivary Duct Carcinoma: A Systematic Review and Meta-Analysis.
Williams CYK; Townson AT; Terry N; Schmitt NC; Sharma A
Laryngoscope; 2023 Mar; 133(3):476-484. PubMed ID: 35567387
[TBL] [Abstract][Full Text] [Related]
7. Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications.
Santana T; Pavel A; Martinek P; Steiner P; Grossmann P; Baněčková M; Skálová A
Hum Pathol; 2019 Nov; 93():37-47. PubMed ID: 31437521
[TBL] [Abstract][Full Text] [Related]
8. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
[TBL] [Abstract][Full Text] [Related]
9. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
Hoda RS; Bowman AS; Zehir A; Razavi P; Brogi E; Ladanyi M; Arcila ME; Wen HY; Ross DS
Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416
[TBL] [Abstract][Full Text] [Related]
10. Frequency of HER2 protein overexpression and HER2 gene amplification in endometrial clear cell carcinoma.
Sukov WR; Zhou J; Geiersbach KB; Keeney GL; Carter JM; Schoolmeester JK
Hum Pathol; 2023 Jul; 137():94-101. PubMed ID: 37094656
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the 2007 and 2013 ASCO/CAP evaluation systems for HER2 amplification in breast cancer.
Pu X; Shi J; Li Z; Feng A; Ye Q
Pathol Res Pract; 2015 Jun; 211(6):421-5. PubMed ID: 25818873
[TBL] [Abstract][Full Text] [Related]
12. HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas.
Mentrikoski MJ; Stoler MH
Am J Surg Pathol; 2014 Jun; 38(6):844-51. PubMed ID: 24698965
[TBL] [Abstract][Full Text] [Related]
13. HER2 IHC Expression and Gene Amplification in p53-aberrant High-grade Endometrial Endometrioid Carcinoma Suggests That This Population May Benefit From HER2 Testing and Targeted Therapy.
Joehlin-Price AS; Komforti MK; Ladwig NR; Devine P; Hoyle C; McCoy L; Sprague C; Astbury C; Hoda R; Chen YY; Garg K
Am J Surg Pathol; 2023 May; 47(5):580-588. PubMed ID: 36939053
[TBL] [Abstract][Full Text] [Related]
14. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
[TBL] [Abstract][Full Text] [Related]
15. PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.
Ni R; Mulligan AM; Have C; O'Malley FP
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):316-24. PubMed ID: 17721278
[TBL] [Abstract][Full Text] [Related]
16.
Zimpfer A; Kdimati S; Mosig M; Rudolf H; Zettl H; Erbersdobler A; Hakenberg OW; Maruschke M; Schneider B
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173881
[TBL] [Abstract][Full Text] [Related]
17. High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines.
Vergara-Lluri ME; Moatamed NA; Hong E; Apple SK
Mod Pathol; 2012 Oct; 25(10):1326-32. PubMed ID: 22699517
[TBL] [Abstract][Full Text] [Related]
18. The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy.
Saigusa N; Hirai H; Tada Y; Kawakita D; Nakaguro M; Tsukahara K; Kano S; Ozawa H; Kondo T; Okami K; Togashi T; Sato Y; Urano M; Kajiwara M; Shimura T; Fushimi C; Shimizu A; Okamoto I; Okada T; Suzuki T; Imanishi Y; Watanabe Y; Sakai A; Ebisumoto K; Sato Y; Honma Y; Yamazaki K; Ueki Y; Hanazawa T; Saito Y; Takahashi H; Ando M; Kohsaka S; Matsuki T; Nagao T
Front Oncol; 2021; 11():779882. PubMed ID: 35186711
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of apocrine salivary duct carcinoma.
Chiosea SI; Williams L; Griffith CC; Thompson LD; Weinreb I; Bauman JE; Luvison A; Roy S; Seethala RR; Nikiforova MN
Am J Surg Pathol; 2015 Jun; 39(6):744-52. PubMed ID: 25723113
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma.
Masubuchi T; Tada Y; Maruya S; Osamura Y; Kamata SE; Miura K; Fushimi C; Takahashi H; Kawakita D; Kishimoto S; Nagao T
Int J Clin Oncol; 2015 Feb; 20(1):35-44. PubMed ID: 24553861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
